Dana-Farber Study Backs FDA Approval of Pembrolizumab-Belzutifan Combo for High-Risk Clear Cell Kidney Cancer Post-Surgery
In a landmark advancement for renal cell carcinoma (RCC) treatment, the U.S. Food and Drug Administration (FDA) has granted approval ...
